Advertisement

Tumor Biology

, Volume 37, Issue 5, pp 6155–6168 | Cite as

Inhibition of phospholipaseD2 increases hypoxia-induced human colon cancer cell apoptosis through inactivating of the PI3K/AKT signaling pathway

  • Maoxi Liu
  • Zhongxue Fu
  • Xingye Wu
  • Kunli Du
  • Shouru Zhang
  • Li Zeng
Original Article

Abstract

Hypoxia is a common feature of solid tumor, and is a direct stress that triggers apoptosis in many human cell types. As one of solid cancer, hypoxia exists in the whole course of colon cancer occurrence and progression. Our previous studies shown that hypoxia induce high expression of phospholipase D2 (PLD2) and survivin in colon cancer cells. However, the correlation between PLD2 and survivin in hypoxic colon cancer cells remains unknown. In this study, we observed significantly elevated PLD2 and survivin expression levels in colon cancer tissues and cells. This is a positive correlation between of them, and co-expression of PLD2 and survivin has a positive correlation with the clinicpatholic features including tumor size, TNM stage, and lymph node metastasis. We also found that hypoxia induced the activity of PLD increased significant mainly caused by PLD2 in colon cancer cells. However, inhibition the activity of PLD2 induced by hypoxia promotes the apoptosis of human colon cancer cells, as well as decreased the expression of apoptosis markers including survivin and bcl2. Moreover, the pharmacological inhibition of PI3K/AKT supported the hypothesis that promotes the apoptosis of hypoxic colon cancer cells by PLD2 activity inhibition may through inactivation of the PI3K/AKT signaling pathway. Furthermore, interference the PLD2 gene expression leaded to the apoptosis of hypoxic colon cancer cells increased and also decreased the expression level of survivin and bcl2 may through inactivation of PI3K/AKT signaling pathway. These results indicated that PLD2 play antiapoptotic role in colon cancer under hypoxic conditions, inhibition of the activity, or interference of PLD2 gene expression will benefit for the treatment of colon cancer patients.

Keywords

PLD2 Apoptosis Hypoxia PI3K/AKT Colon cancer 

Notes

Acknowledgments

This work was supported by the National Natural Science Foundation of China, no. 81201916. The authors gratefully thank Laboratory Research Center of the First Affiliated Hospital of Chongqing Medical University for providing equipment support.

Compliance with ethical standards

Conflicts of interest

None

References

  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics,2012. CA Cancer J Clin. 2012;62:10–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.CrossRefPubMedGoogle Scholar
  3. 3.
    Igney FH, Krammer PH. Death and anti-death: tumor resistance to apoptosis. Nat Rev Cancer. 2002;2:277–88.CrossRefPubMedGoogle Scholar
  4. 4.
    Nakashima S, Nozawa Y. Possible role of phospholipase D in cellular differentiation and apoptosis. Chem Phys Lipids. 1999;98:153–64.CrossRefPubMedGoogle Scholar
  5. 5.
    Uchida N, Okamura S, Kuwano H. Phospholipase D activity in human gastric carcinoma. Anticancer Res. 1999;19:77–86.Google Scholar
  6. 6.
    Ahn MJ, Park SY, Kim WK, Cho JH, Chang BJ, Kim DJ, et al. A single nucleotide polymorphism in the phospholipase D1 gene is associated with risk of non-small lung cancer. Int J Biomed Sci. 2012;8:121–8.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Toschi A, Edelstein J, Rockwell P, Ohh M, Foster DA. HIF alpha expression in VHL-deficient renal cancer cells is dependent on phospholipase D. Oncogene. 2008;27:2746–53.CrossRefPubMedGoogle Scholar
  8. 8.
    Noh DY, Ahn SJ, Lee RA, Park IA, Kim JH, Suh PG, et al. Overexpression of phospholipase D in human breast cancer tissues. Cancer Lett. 2000;161:207–14.CrossRefPubMedGoogle Scholar
  9. 9.
    Cho JH, Hong S-K, Kim E-Y, Park S-Y, Park C-H, et al. Overexpression of phospholipase D suppress taxotere-induced cell death in stomach cancer cells. Biochim Biophys Acta. 2008;1783:912–3.CrossRefPubMedGoogle Scholar
  10. 10.
    Kim K-OK, Lee K-H, Kim Y-H, Park S-K, Han J-S. Anti-apoptotic role of phospholipase D isozymes in the glutamate-induced cell death. Exp Mol Med. 2003;35:38–45.CrossRefPubMedGoogle Scholar
  11. 11.
    Zhong M, Shen Y, Yang Z, Joseph T, Jackson D, et al. Phospholipase D prevent apoptosis in v-Src-transformed rat fibroblasts and MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun. 2003;302:615–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Peng JHF, Feng Y, Rhodes PG. Down-regulation of phospholipase D2 mRNA in neonatal rat brainstem and cerebellum after hypoxia-ischemia. Neurochem Res. 2006;31:1191–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Mozzicato S, Joshi BV, Jacobson KA, Liang BT. Role of direct RhoA phospholipase D1 interaction in mediating adenosine-induced protection from cardiac ischemia. FASEB J. 2004;18:406–8.PubMedGoogle Scholar
  14. 14.
    Lee SD, Lee BD, Han JM, Kim JH, Kim Y, et al. Phospholipase D2 activity suppresses hydrogen peroxide-induced apoptosis in PC12 cells. J Neurochem. 2000;75:1053–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Yamakawa H, Banno Y, Nakashima S, Sawada M, Yamada J, Yoshimura S, et al. Increased phospholipase D2 activity during hypoxia-induced death of PC12 cells: its possible anti-apoptotic role. Neurol Rep. 2000;16:3647–50.Google Scholar
  16. 16.
    Ghim J, Moon JS, Lee CS, Lee J, Song P, Lee A. Endothelial deletion of phospholipase D2 reduces hypoxic response and pathological angiogenesis. Arterioscler Thromb Vasc Biol. 2014;34:1697–703.CrossRefPubMedGoogle Scholar
  17. 17.
    Oshimoto H, Okamura S, Yoshida M, Mori M. Increased activity and expression of phospholipase D2 in human colorectal cancer. Oncol Res. 2003;14:31–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Saito M, Iwadate M, Higashimoto M, Ono K. Expression of phospholipase D2 in human colorectal carcinoma. Oncol Rep. 2007;18:1329–34.PubMedGoogle Scholar
  19. 19.
    Yamada Y, Hamajima N, Kato T, Iwata H. Association of a polymorphism of the phospholipase D2 gene with the prevalence of colorectal cancer. J Mol Med. 2003;81:126–31.CrossRefPubMedGoogle Scholar
  20. 20.
    Wu XY, Fu ZX, Wang XH, et al. Identification of differential proteins in colon cancer SW480 cells with HIF1-alpha silence by proteome analysis. Neoplasma. 2010;57:299–305.CrossRefPubMedGoogle Scholar
  21. 21.
    Maoxi L, Kunli D, Zhongxue F, Shouru Z, Xingye W. Hypoxia-inducible factor 1-alpha up-regulates the expression of phospholipase D2 in colon cancer cells under hypoxic conditions. Med Oncol. 2015;32:394.CrossRefGoogle Scholar
  22. 22.
    Zhang S, Liu B, Zhang B, Fan Z. The effect of survivin expression on the apoptosis and proliferation of hypoxic human pulmonary arterial smooth muscle cells. Zhonghua jiehe he huxi zazi. 2015;38:45–9.Google Scholar
  23. 23.
    Wu X, Zhongxue F, Wang X. Effect of hypoxia-inducible factor 1-α on surviving in colorectal cancer. Mol Med Rep. 2010;3:409–15.PubMedGoogle Scholar
  24. 24.
    K.J.Oh, S.C. Lee, H.j. Choi, D.Y.Oh, S.C. Kim, D.S. Min, J.M. Kim, K.S. Lee, J.S. Han. Role of phospholipase D2 in anti-apoptotic signaling through increased expression of Bcl2 and Bcl-xL.J. Cell. Biochem. 2007.Google Scholar
  25. 25.
    Song H, Han l-Y, Kim Y, Kim Young H, Cho l-W, et al. The NADPH oxidase inhibitor DPI can abolish hypoxia-induced apoptosis of human kidney proximal tubular epithelial cells through Bcl2 up-regulation via ERK activation without ROS reduction. Life Sci. 2015;126:69–75.CrossRefPubMedGoogle Scholar
  26. 26.
    Vivanco L, Sawyers C. The phosphatidylinositol 3-Kinase-AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489–501.CrossRefPubMedGoogle Scholar
  27. 27.
    Momoko YAMADA, Banno Y, Yoh TAKUWA, Masahiro KODA, Yoshinori NOZAWA. Overexpression of phospholipase D prevents actinomycin D-induced apoptosis through potentiation of phosphoinositide 3-kinase signaling pathway in Chinese-hamster ovary cells. Biochem J. 2004;378:649–56.CrossRefGoogle Scholar
  28. 28.
    Yuhong C, Vanessa R, Foster DA. Alternative phospholipase D/mTOR survival signal in human breast cancer cells. Oncogene. 2005;24:672–9.CrossRefGoogle Scholar
  29. 29.
    Wittekind C, Compton CC, Greene FL, Sobin LH. TNM residual tumor classification revised. Cancer. 2002;94:2511–6.CrossRefPubMedGoogle Scholar
  30. 30.
    Yu C, Zhang Z, Liao W, Zhao X, Liu L, Wu Y, et al. The tumor-suppressor gene NKX2-8 suppresses bladder cancer proliferation through upregulation of FOXO3a and inhibition of the MEK/ERK signaling pathway. Carcinogenesis. 2012;33:678–86.CrossRefPubMedGoogle Scholar
  31. 31.
    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta DeltaC(T)) method. Methods. 2001;25:402–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Oh JW, Kim EY, koo BS, Lee HB, Kim KS, Han JS. Der f 2 activates phospholipase D in human T lymphocytes from Dermatophagoides farinae specific allergic individuals: involvement of protein kinase C-α. Exp Mol Med. 2004;36:486–92.CrossRefPubMedGoogle Scholar
  33. 33.
    Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Thomas P. Mathews, Salisha Hill,Kristie L. Rose,Pavlina T. Ivanova,Craig W. Lindsley and H. Alex Brown, Human phospholipase D activity transiently regulates pyrimidine biosynthesis in malignant gliomas. ACS Chemical Biology. 2015. PMID:25646564.Google Scholar
  35. 35.
    Kang DW, Min DS. Positive feedback regulation between phospholipase D and Wnt signaling promotes Wnt-driven anchorage-independent growth of colorectal cancer cells. Plos One. 2010;5:2109.CrossRefGoogle Scholar
  36. 36.
    Kang DW, Choi KY, Mindo S. Phospholipase D meets Wnt signaling a new target for cancer therapy. Cancer Res. 2011;71:293–7.CrossRefPubMedGoogle Scholar
  37. 37.
    Jones D, Morgan C, Cockcroft S. Phospholipase D and membrane traffic. Potential roles in regulated exocytosis, membrane delivery and vesicle budding. Biochim Biophys Acta. 1999;1439:229–44.CrossRefPubMedGoogle Scholar
  38. 38.
    Su W, Chen Q, Frohman M. Targeting phospholipase D with small-molecule inhibitors as a potential therapeutic approach for cancer metastasis. Future Oncol. 2009;5:1477–86.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Lee YH, Bae YS. Phospholipase D2 downregulation reduces cellular senescence through a reactive oxygen species P53-P21 pathway. FEBS Lett. 2014;588:3251–8.CrossRefPubMedGoogle Scholar
  40. 40.
    Gomez-Cambronero J. Phospholipase D in cell signaling: from a myriad of cell functions to cancer growth and metastasis. J Biol Chem. 2014;289:22557–66.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Saito M, Manabu I, Masahi H, Koichiro O, et al. Expression of phospholipase D2 in human colorectal carcinoma. Oncol Rep. 2007;18:1329–34.PubMedGoogle Scholar
  42. 42.
    Liu L, Li F, Cardeui JA, et al. Rapamycin inhibits cell mobility by suppression of mTOR-mediated S6K1 and 4E-BPI pathways. Oncogene. 2006;25:7029–40.CrossRefPubMedGoogle Scholar
  43. 43.
    Wang Q, Zhou Y, Evers BM. Pkc delta-mediated regulation of FLIP expression in human colon cancer cells. Int J Cancer. 2006;118:326–34.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Lin J, Guan Z, Wang C, et al. Inhibitor of differentiation 1 contributes to head and neck squamous cell carcinoma survival via the NF-kappaB/survivin and phosphoionositide 3-kinase/Akt signaling pathways. Clin Cancer Res. 2010;16:77–87.CrossRefPubMedGoogle Scholar
  45. 45.
    Li W, Wang H, Kuang CY, et al. An essential role for the Id1/PI3K/Akt/NFκB/surviving signalling pathway in promoting the proliferation of endothelial progenitor cells in vitro. Mol Cell Biochem. 2012;363:135–45.CrossRefPubMedGoogle Scholar
  46. 46.
    Yang X-C, Wang X, Luo L, Dong DH, Yu QC, Wang XS, et al. RNA interference suppression of A100A4 reduces the growth and metastatic phenotype of human renal cancer cells via NF-κB dependent MMP-2 and bcl2 pathway. Eur Rev Med Pharmacol Sci. 2013;17:1669–80.PubMedGoogle Scholar
  47. 47.
    Mi Hee P, Bong-Hyun A, Yong-Kil H, Do Sik M. Overexpression of phospholipase D enhances matrix metalloproteinase-2 expression and glioma cell invasion via protein kinase C and protein kinase a/NF-κB/SP1-mdiated signaling pathways. Carcinogenesis. 2009;30:356–65.Google Scholar
  48. 48.
    Dong Woo K, Do Sik M. Platelet derived growth factor increases phospholipase D1 but not phospholipase D2 expression via NFκB signaling pathway and enhances invasion of breast cancer cells. Cancer Lett. 2010;294:125–33.CrossRefGoogle Scholar
  49. 49.
    Thomas RP, Farrow BJ, Kim S, May MJ, Hellmich MR, Evers BM. Selective targeting of the nuclear factor-kappaB pathway enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated pancreatic cancer cell death. Surgery. 2002;132:127–34.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of Gastrointestinal SurgeryThe First Affiliated Hospital of Chongqing Medical UniversityChongqingChina
  2. 2.Department of traditional Chinese MedicineThe First Affiliated Hospital of Chongqing Medical UniversityChongqingChina

Personalised recommendations